{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T20:44:05Z","timestamp":1763585045344,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2001,11,1]],"date-time":"2001-11-01T00:00:00Z","timestamp":1004572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2001,11,1]],"date-time":"2001-11-01T00:00:00Z","timestamp":1004572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2001,11]]},"DOI":"10.4158\/ep.7.6.430","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T23:40:11Z","timestamp":1365205211000},"page":"430-437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Syndrome of Lipodystrophy, Hyperlipidemia, Insulin Resistance, and Diabetes in Treated Patients with Human Immunodeficiency Virus Infection"],"prefix":"10.1016","volume":"7","author":[{"given":"Alan L.","family":"Graber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP.7.6.430_bb0005","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.CIR.100.7.700","article-title":"Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors: the Swiss HIV Cohort Study","volume":"100","author":"Periard","year":"1999","journal-title":"Circulation."},{"key":"10.4158\/EP.7.6.430_bb0010","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS."},{"key":"10.4158\/EP.7.6.430_bb0015","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0140-6736(97)11443-X","article-title":"\u201cBuffalo hump\u201d in men with HIV-1 infection","volume":"351","author":"Lo","year":"1998","journal-title":"Lancet."},{"key":"10.4158\/EP.7.6.430_bb0020","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1097\/00002030-199912240-00002","article-title":"Fat distribution and metabolic changes in patients with HIV infection","volume":"13","author":"Safrin","year":"1999","journal-title":"AIDS."},{"key":"10.4158\/EP.7.6.430_bb0025","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet."},{"issue":"Suppl 2","key":"10.4158\/EP.7.6.430_bb0030","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1086\/313854","article-title":"HIV protease inhibitor-related lipodystrophy syndrome","volume":"30","author":"Carr","year":"2000","journal-title":"Clin Infect Dis."},{"key":"10.4158\/EP.7.6.430_bb0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00126334-200001010-00005","article-title":"Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection","volume":"23","author":"Mulligan","year":"2000","journal-title":"J Acquir Immune Defic Syndr."},{"key":"10.4158\/EP.7.6.430_bb0040","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/archinte.160.13.2050","article-title":"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study","volume":"160","author":"Tsiodras","year":"2000","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP.7.6.430_bb0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00002030-200001070-00005","article-title":"Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study","volume":"14","author":"Saint-Marc","year":"2000","journal-title":"AIDS."},{"key":"10.4158\/EP.7.6.430_bb0050","first-page":"1932","article-title":"Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women","volume":"84","author":"Hadigan","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.7.6.430_bb0055","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0140-6736(99)06102-4","article-title":"Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy","volume":"354","author":"Brinkman","year":"1999","journal-title":"Lancet."},{"key":"10.4158\/EP.7.6.430_bb0060","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1097\/00002030-199911120-00008","article-title":"Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy","volume":"13","author":"Domingo","year":"1999","journal-title":"AIDS."},{"key":"10.4158\/EP.7.6.430_bb0065","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1136\/bmj.280.6230.1500","article-title":"Insulin-induced lipoatrophy: evidence for an immune pathogenesis","volume":"1","author":"Reeves","year":"1980","journal-title":"Br Med J."},{"key":"10.4158\/EP.7.6.430_bb0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2337\/diacare.19.3.255","article-title":"Human insulin-induced lipoatrophy: successful treatment using a jet-injection device [erratum in Diabetes Care. 1997;20:119]","volume":"19","author":"Logwin","year":"1996","journal-title":"Diabetes Care."},{"key":"10.4158\/EP.7.6.430_bb0075","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1210\/jcem.84.6.5740","article-title":"Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy","volume":"84","author":"Yanovski","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.7.6.430_bb0080","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0140-6736(46)90528-4","article-title":"Lipodystrophy and hepatomegaly with diabetes, lipemia and other metabolic disturbances","volume":"1","author":"Lawrence","year":"1946","journal-title":"Lancet."},{"key":"10.4158\/EP.7.6.430_bb0085","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/BF00184724","article-title":"Lipoatrophic diabetes","volume":"71","author":"Dorfler","year":"1993","journal-title":"Clin Investig."},{"key":"10.4158\/EP.7.6.430_bb0090","first-page":"3089","article-title":"LMNA R482Q mutation in partial lipodystrophy associated with reduced plasma leptin concentration","volume":"85","author":"Hegele","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.7.6.430_bb0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/43448","article-title":"Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy","volume":"401","author":"Shimomura","year":"1999","journal-title":"Nature."},{"key":"10.4158\/EP.7.6.430_bb0100","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2337\/diabetes.49.6.883","article-title":"The perils of portliness: causes and consequences of visceral adiposity","volume":"49","author":"Montague","year":"2000","journal-title":"Diabetes."},{"key":"10.4158\/EP.7.6.430_bb0105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2337\/diabetes.48.1.94","article-title":"Surgical removal of visceral fat reverses hepatic insulin resistance","volume":"48","author":"Barzilai","year":"1999","journal-title":"Diabetes."},{"key":"10.4158\/EP.7.6.430_bb0110","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM199804303381808","article-title":"HIV-protease inhibitors","volume":"338","author":"Flexner","year":"1998","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.7.6.430_bb0115","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(98)03391-1","article-title":"Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance","volume":"351","author":"Carr","year":"1998","journal-title":"Lancet."},{"key":"10.4158\/EP.7.6.430_bb0120","doi-asserted-by":"crossref","first-page":"20251","DOI":"10.1074\/jbc.C000228200","article-title":"The mechanism of insulin resistance caused by HIV protease inhibitor therapy","volume":"275","author":"Murata","year":"2000","journal-title":"J Biol Chem."},{"key":"10.4158\/EP.7.6.430_bb0125","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.284.4.472","article-title":"Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial","volume":"284","author":"Hadigan","year":"2000","journal-title":"JAMA."},{"key":"10.4158\/EP.7.6.430_bb0130","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-133-4-200008150-00009","article-title":"Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes","volume":"133","author":"Arioglu","year":"2000","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP.7.6.430_bb0135","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2337\/diacare.22.2.288","article-title":"Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes","volume":"22","author":"Kelly","year":"1999","journal-title":"Diabetes Care."},{"key":"10.4158\/EP.7.6.430_bb0140","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2337\/diacare.22.6.908","article-title":"Effect of troglitazone on body fat distribution in type 2 diabetic patients","volume":"22","author":"Mori","year":"1999","journal-title":"Diabetes Care."},{"key":"10.4158\/EP.7.6.430_bb0145","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1592\/phco.20.7.727.35179","article-title":"Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities","volume":"20","author":"Thomas","year":"2000","journal-title":"Pharmacotherapy."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20393009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20393009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/UPRVT1194R0LY02M.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:41:18Z","timestamp":1761514878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20393009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["S1530891X20393009"],"URL":"https:\/\/doi.org\/10.4158\/ep.7.6.430","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2001,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Syndrome of Lipodystrophy, Hyperlipidemia, Insulin Resistance, and Diabetes in Treated Patients with Human Immunodeficiency Virus Infection","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.7.6.430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2001 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}